menu
    • menu
    [{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Foscarnet Sodium","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex?rocuronium chelating complex","graph1":"Musculoskeletal","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eribulin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by GLAND PHARMA LIMITED

    Menu

    GLAND PHARMA LIMITED

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprostene Bunod

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Receives Tentative FDA Approval for Latanoprostene Solution

                            Details : Latanoprostene bunod is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

                            Brand Name : Vyzulta-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : Latanoprostene Bunod

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection

                            Details : Eribulin Mesylate, a non-taxane microtubule dynamics inhibitor used for the treatment of breast cancer, is expected to be the first generic approval on the market.

                            Brand Name : Eribulin Mesylate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2024

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Launches Generic Cancer Treatment Drug in US

                            Details : Bortezomib-Generic is therapeutically equivalent to Takeda Pharmaceuticals' Velcade for Injection, is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.

                            Brand Name : Bortezomib-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2022

                            Lead Product(s) : Bortezomib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Receives Tentative Approval for Sugammadex Injection

                            Details : Sugammadex injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL is generic bioequivalent and therapeutically equivalent to Bridion injection of Merck used to reverse the effects of the muscle relaxants rocuronium bromide and vecuronium bromide given to pat...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2021

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foscarnet Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Receives Approval for Generic Foscarnet Sodium Injection

                            Details : Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir® Injection, 24 mg/mL, of Clinigen Healthcare Limited.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 22, 2021

                            Lead Product(s) : Foscarnet Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth